Ji Miao-Jin, Yang Jiao, Gao Zhi-Qiang, Zhang Liang, Liu Chao
Jiangsu Province Key Laboratory of Anesthesiology and Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, School of Anesthesiology, Xuzhou Medical University, Xuzhou, China.
Jiangsu Province Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, China.
Front Neurosci. 2021 Feb 24;15:642493. doi: 10.3389/fnins.2021.642493. eCollection 2021.
Both pain and psychiatric disorders, such as anxiety and depression, significantly impact quality of life for the sufferer. The two also share a strong pathological link: chronic pain-induced negative affect drives vulnerability to psychiatric disorders, while patients with comorbid psychiatric disorders tend to experience exacerbated pain. However, the mechanisms responsible for the comorbidity of pain and psychiatric disorders remain unclear. It is well established that the kappa opioid system contributes to depressive and dysphoric states. Emerging studies of chronic pain have revealed the role and mechanisms of the kappa opioid system in pain processing and, in particular, in the associated pathological alteration of affection. Here, we discuss the key findings and summarize compounds acting on the kappa opioid system that are potential candidates for therapeutic strategies against comorbid pain and psychiatric disorders.
疼痛和精神疾病,如焦虑症和抑郁症,都会对患者的生活质量产生重大影响。这两者还存在着紧密的病理联系:慢性疼痛引发的负面影响会导致患精神疾病的易感性,而患有共病精神疾病的患者往往会经历更严重的疼痛。然而,疼痛和精神疾病共病的机制仍不清楚。众所周知,κ阿片系统与抑郁和烦躁状态有关。对慢性疼痛的最新研究揭示了κ阿片系统在疼痛处理过程中的作用和机制,特别是在相关情感病理改变方面。在此,我们讨论关键发现,并总结作用于κ阿片系统的化合物,这些化合物是针对共病疼痛和精神疾病治疗策略的潜在候选药物。